These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16219581)

  • 1. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells.
    Hipp S; Ringshausen I; Oelsner M; Bogner C; Peschel C; Decker T
    Haematologica; 2005 Oct; 90(10):1433-4. PubMed ID: 16219581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
    Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.
    Venkataraman G; Maududi T; Ozpuyan F; Bahar HI; Izban KF; Qin JZ; Alkan S
    Leuk Res; 2006 Nov; 30(11):1377-84. PubMed ID: 16624404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
    Costa LJ
    Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
    Jares P; Colomer D; Campo E
    Nat Rev Cancer; 2007 Oct; 7(10):750-62. PubMed ID: 17891190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma in relapse: the role of emerging new drugs.
    Diefenbach CS; O'Connor OA
    Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
    Haritunians T; Mori A; O'Kelly J; Luong QT; Giles FJ; Koeffler HP
    Leukemia; 2007 Feb; 21(2):333-9. PubMed ID: 17136116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
    Georgakis GV; Li Y; Younes A
    Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
    Park IW; Reddy MV; Reddy EP; Groopman JE
    Oncogene; 2007 Aug; 26(38):5635-42. PubMed ID: 17369860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temsirolimus for the treatment of mantle cell lymphoma.
    Hess G
    Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
    Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mantle cell lymphoma: advances in biology and therapy.
    Smith MR
    Curr Opin Hematol; 2008 Jul; 15(4):415-21. PubMed ID: 18536582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging.
    Zhuo L; Cai G; Liu F; Fu B; Liu W; Hong Q; Ma Q; Peng Y; Wang J; Chen X
    Mech Ageing Dev; 2009 Oct; 130(10):700-8. PubMed ID: 19698731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
    Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.